Igrelimogene litadenorepvec

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameIgrelimogene litadenorepvec
Drug Alias NameAD5/3-E2F-D24-TNFA-IRES-IL2Ad5/3-E2F-d24-hTNFa-IRES-hIL2igrelimogene litadenorepvecTNFalpha and IL-2 coding oncolytic adenovirus TILT-123PM1016 +[7] 
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionCell death stimulantsTumor necrosis factor α stimulantsInterleukin-2 stimulants +[4] 
TargetsTumor necrosis factor αInterleukin-2E2F transcription factors
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsLung Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmarkFrance +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTilt Biotherapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTilt Biotherapeutics Ltd +[2] 
Inactive CompaniesGenIbet Biopharmaceuticals SA
Active IndicationsSolid tumoursFallopian Tube NeoplasmsLung Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A